Astrocyte Pharmaceuticals

What Astrocyte Pharmaceuticals does

Astrocyte Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in 2014 by William S. Korinek, Ph.D. (CEO) and James D. Lechleiter, Ph.D., headquartered in Groton, CT with an additional office in Cambridge, MA. The company is developing cerebroprotective therapeutics for acute and chronic brain injuries, with a lead candidate AST-004, a novel small-molecule selective agonist of adenosine A1 and A3 receptors designed to enhance mitochondrial ATP production in astrocytes by stimulating IP3-mediated Ca2+ release and activating Ca2+-sensitive dehydrogenases in the TCA cycle. This astrocyte-targeting mechanism represents a fundamentally different approach from traditional neuroprotective strategies that act directly on neurons, and is being investigated for acute ischemic stroke, traumatic brain injury (TBI), concussion, and Alzheimer's disease.

AST-004 is being developed in two formulations: an intravenous injection intended for emergency professionals in hospital settings for acute stroke and TBI, and an oral tablet formulation intended for field use in sports, roadside, and battlefield scenarios. A second pipeline candidate, AST-008, targets pain and migraine indications but remains undisclosed in detail. The company has completed two Phase 1 safety trials in Europe involving 80 healthy volunteers with no significant adverse effects, initiated a Phase 1B extended infusion study in the Netherlands, achieved FDA IND clearance for acute ischemic stroke in March 2024, and launched a Phase 2 STARFAST trial in Australian Rules Football players for concussion in June 2025.

The business model is licensing-, co-development-, and eventual product sales-driven, with no commercial revenue at present. Operations are funded by a combination of private equity (over $25M total, including a $6M+ 2023 pre-Series B Bridge led by Dreavent Capital) and non-dilutive grants from the NIH and MTEC (totaling roughly $6.8M across multiple awards from 2018 to 2025). The company is supported by a Scientific and Clinical Advisory Board drawn from leading U.S. stroke and TBI centers (Yale, Stanford, UCLA, UPMC, Emory), and its leadership team is anchored by former Pfizer senior R&D executives with deep CNS drug development experience.

Name

Astrocyte Pharmaceuticals

Legal name

Astrocyte Pharmaceuticals Inc.

Website

https://astrocytepharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Astrocyte Pharmaceuticals is a clinical-stage biopharmaceutical company developing AST-004, a novel small-molecule adenosine A1/A3 receptor agonist that enhances astrocyte mitochondrial ATP production to provide neuroprotection in stroke, traumatic brain injury, concussion, and Alzheimer's disease patients.

Ownership category

akta.pro rank

Product category

Neuroprotective Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Cerebroprotective therapeutics
• Neuroprotective drug development
• Traumatic brain injury treatment
• Acute ischemic stroke therapy
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. Pharmaceutical Drug Development and Licensing: Clinical-stage biopharmaceutical company developing AST-004 for stroke, TBI, concussion, and Alzheimer's disease. Revenue will be generated through drug licensing, co-development partnerships, and eventual product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Astrocyte Pharmaceuticals is a clinical-stage biopharmaceutical company developing AST-004, a novel small molecule selective agonist of adenosine A1 and A3 receptors designed to provide cerebroprotection following acute brain injuries. The drug enhances mitochondrial energy metabolism in astrocytes to reduce tissue damage, brain swelling, and neuroinflammation. AST-004 is being developed in both IV formulation for hospital emergency use (acute ischemic stroke, severe TBI) and an oral 'field' formulation for concussion, mild TBI, and chronic neurodegenerative diseases, with additional pipeline candidate AST-008 targeting pain and migraine.

Product overview

Astrocyte Pharmaceuticals is developing a pipeline of cerebroprotective therapeutics centered on two candidates: AST-004 (core product) and AST-008. AST-004 is a novel small molecule adenosine A1/A3 receptor agonist currently in Phase II clinical trials for acute brain injuries including acute ischemic stroke, sports-related concussion, mild TBI, moderate-severe TBI, and Alzheimer's disease. It is administered via intravenous injection, with an oral field formulation in preclinical development. AST-008 is an undisclosed therapeutic candidate for pain, migraine, and other CNS indications. The company is also advancing an oral tablet formulation of AST-004 for concussion and mild TBI.

Differentiator

Problem solved

Functional benefit

Products and services

• AST-004 Novel small molecule selective agonist of adenosine A1 and A3 receptors designed to enhance mitochondrial energy metabolism in astrocytes, providing cerebroprotection for acute ischemic stroke, traumatic brain injury, concussion, and neurodegenerative diseases such as Alzheimer's. Available in intravenous formulation for hospital emergency use and oral tablet formulation in development for field deployment. Currently in Phase 2 clinical trials.
• AST-008

Quantifiable outcome

• 64% reduction in brain lesion growth in non-human primate stroke model
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core.

• SPARK Trials / Adelaide Football LeaguecoreStrategic or Co-development Partner · 1 June 2025Collaboration for STARFAST Phase 2 clinical trial in Australian Rules Football players suffering sports-related concussions. Conducted in Adelaide, Australia with players receiving AST-004 or placebo within 6 hours of concussion. First-of-its-kind study in athletes without routine sub-concussive impacts.
• QPS (Groningen, Netherlands)coreStrategic or Co-development Partner · 1 April 2023Clinical research organization conducting Phase 1B extended infusion study of AST-004 in healthy volunteers at their site near Budapest, Hungary (Kistarcsa). Study assessed safety, tolerability, and pharmacokinetics of AST-004 administered as loading dose followed by 6-hour continuous infusion.
• University of Pittsburgh Medical Center (UPMC) Stroke InstitutecoreStrategic or Co-development PartnerDr. Raul G. Nogueira serves as Professor of Neurology and Neurosurgery and Division Chief of Cerebrovascular Medicine at UPMC, and as advisor to Astrocyte. He has led many stroke thrombectomy studies and brings extensive stroke clinical trial expertise.
• Stanford Stroke CentercoreStrategic or Co-development PartnerDr. Gregory W. Albers, Director of Stanford Stroke Center since 1992, serves as advisor. His research using advanced imaging to expand stroke treatment window has been instrumental in clinical trial design. Led all 3 DEFUSE studies that led to extending stroke treatment window to 24 hours.
• UCLA Stroke UnitcoreStrategic or Co-development PartnerDr. Jeffrey L. Saver serves as Chair of Astrocyte's Clinical Advisory Board. As Director of UCLA Stroke Unit since 1995, he has been PI for groundbreaking studies including FAST-MAG, SWIFT-PRIME, and DAWN. Provided key commentary on AST-004's potential for pre-hospital use.
• Yale School of Medicine / Yale Center of Brain & Mind HealthcoreStrategic or Co-development PartnerDr. Kevin Sheth serves as Chief Medical Advisor. As Chief of Division of Neurocritical Care & Emergency Neurology and Director of Yale Center of Brain & Mind Health, he is recognized for leadership in prevention, acute treatment, and recovery trials of brain injury. Co-Director of Yale's Center for Brain & Mind Health.
• Emory University School of MedicinecoreStrategic or Co-development PartnerDr. David W. Wright serves as advisor. As Chair and Professor of emergency medicine and Director of Emergency Neurosciences, he is an international clinical leader in TBI research. Was PI for ProTECT III multicenter clinical trial and one of top 3 NIH-funded emergency medicine researchers in US.
• Hamamatsu Pharma Research (Japan)coreStrategic or Co-development PartnerCollaborated on non-human primate stroke studies published in Stroke journal. Contributed to preclinical efficacy studies demonstrating AST-004's significant cerebroprotective effects in primate models of stroke.
• University of Texas Health Science Center at San AntoniocoreStrategic or Co-development PartnerCo-founded by Dr. James D. Lechleiter, Professor of Cellular and Structural Biology. Dr. Lechleiter's research investigates molecular and cellular mechanisms of protection during ischemic stress, acute brain injury and aging. His work focuses on astrocyte mitochondrial ATP production.
• University of Warwick (UK)coreStrategic or Co-development PartnerAcademic collaborator on non-human primate stroke research published in Stroke journal. Contributed to international research effort demonstrating AST-004 efficacy in primate stroke model.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NoNO Inc. Toronto-based clinical-stage biotech developing nerinetide, a PSD-95 inhibitor neuroprotective for acute ischemic stroke. Directly comparable as a clinical-stage neuroprotection company pursuing Phase 3 efficacy in stroke with a novel cerebroprotective mechanism.
• ZZ Biotech: Clinical-stage company developing 3K3A-APC, a recombinant variant of activated protein C with neuroprotective and anti-inflammatory properties for ischemic stroke and TBI. Closely comparable as a small clinical-stage biopharma focused on cerebroprotection across the same stroke and TBI indications.
• Remedy Pharmaceuticals: Clinical-stage company developing Cirara (intravenous glyburide) for large hemispheric infarction and other CNS edema indications. Comparable as a clinical-stage neuroprotection company pursuing severe brain injury indications with hospital-administered IV therapy.

Emerging players

• BrainQ Technologies: Israeli medtech/biotech developing electromagnetic field therapy for ischemic stroke recovery. Comparable as an emerging company pursuing non-pharmaceutical approaches to post-stroke neuroprotection and recovery, intersecting with Astrocyte's stroke and TBI focus.
• Banyan Biomarkers: Company that developed and received FDA clearance for the first blood test for TBI (GFAP/UCH-L1 biomarkers). Closely linked to Astrocyte via SAB member Jackson Streeter (former Banyan CEO). Comparable as a TBI-focused company addressing the same patient population through a diagnostic rather than therapeutic modality.
• Quanterix: Company developing ultra-sensitive biomarker assays including GFAP/NfL for TBI and neurodegeneration research. Comparable as an emerging player in TBI diagnostics and CNS biomarker measurement, addressing overlapping patient stratification needs in TBI and concussion.

Broad incumbents

• Sage Therapeutics: Commercial-stage CNS biopharma (zurzuvae approved for postpartum depression; zuranolone). Comparable as a CNS-focused specialty biopharma with similar capital-intensity clinical development in neuroscience, providing a relevant template for late-stage CNS biopharma economics.
• Axsome Therapeutics: Commercial-stage CNS biopharma with approved products for migraine (AXS-07) and depression (AXS-05). Comparable as a CNS specialty biopharma that scaled from clinical-stage to commercialization with a similar indication breadth strategy.
• Penumbra: Commercial-stage company specializing in thrombectomy and neurovascular devices for stroke treatment. Not a direct competitor but addresses the same acute ischemic stroke patient population via mechanical reperfusion rather than pharmacological neuroprotection.
• Biogen: Large established CNS biopharma with neurology and neurodegeneration franchises. Relevant as the archetypal large-acquirer/partner for clinical-stage CNS assets and as a benchmark for indication coverage across neurology and neurodegenerative diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/astrocytepharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds14 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astrocyte Pharmaceuticals